# EDGAR Filing Document

**Accession Number:** 0002109744
**File Stem:** 0001213900-26-017548
**Filing Date:** 2026-2
**Character Count:** 6681
**Document Hash:** 42b1f65d312ab90016a6dfc54d1a1aaa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-017548.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001213900-26-017548

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260217

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ross Michael A.
- **CENTRAL INDEX KEY:** 0002109744

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43128
- **FILM NUMBER:** 26644330

**MAIL ADDRESS:**
- **STREET 1:** 5810 GAITHER ROAD
- **STREET 2:** SUITE 235
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20877
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 20/20 Biolabs, Inc.
- **CENTRAL INDEX KEY:** 0001139685
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522272107
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 9430 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 2404536339

**MAIL ADDRESS:**
- **STREET 1:** 15810 GAITHER ROAD, SUITE 235
- **STREET 2:** SUITE 235
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20877

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 20/20 GeneSystems, Inc.
- **DATE OF NAME CHANGE:** 20150922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 20/20 GENE SYSTEMS INC
- **DATE OF NAME CHANGE:** 20010502

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ross Michael A.<br><sub>(Last) (First) (Middle)</sub><br>C/O 20/20 BIOLABS, INC.<br>15810 GAITHER ROAD, SUITE 235<br><sub>(Street)</sub><br>GAITHERSBURG, MD 20877<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>20/20 Biolabs, Inc. [ AIDX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-17 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A-2 Preferred Stock<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 31 | <sup>(1)</sup> | D |  |
| Stock Option<sup>(2)</sup> | 2019-08-01 | 2029-07-31 | Common Stock | 48780 | $0.82 | D |  |
| Stock Option<sup>(3)</sup> | 2021-01-28 | 2031-01-27 | Common Stock | 76628 | $1.044 | D |  |
| Stock Option<sup>(4)</sup> | <sup>(4)</sup> | 2032-02-01 | Common Stock | 37584 | $1.0643 | D |  |
| Stock Option<sup>(5)</sup> | 2022-02-01 | 2032-02-01 | Common Stock | 37583 | $1.0643 | D |  |
| Stock Option<sup>(6)</sup> | <sup>(6)</sup> | 2033-01-01 | Common Stock | 30000 | $1.74 | D |  |
| Stock Option<sup>(7)</sup> | <sup>(7)</sup> | 2034-07-01 | Common Stock | 30000 | $2.55 | D |  |

---

### Footnotes:

(1) Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.

(2) On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.

(3) On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.

(4) On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.

(5) On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.

(6) On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

(7) On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

**Signature:** /s/ Michael A. Ross  
**Date:** 2026-02-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**